title: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
abstract: In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of antibacterial therapy were randomized (1:1:1) to receive amphotericin B lipid complex (ABLC) at a dose of 5 mg/kg/d (n=78), liposomal amphotericin B (L Amph) at a dose of 3 mg/kg/d (n=85), or L Amph at a dose of 5 mg/kg/d (n=81). L Amph (3 mg/kg/d and 5 mg/kg/d) had lower rates of fever (23.5% and 19.8% vs. 57.7% on day 1; P<.001), chills/rigors (18.8% and 23.5% vs. 79.5% on day 1; P<.001), nephrotoxicity (14.1% and 14.8% vs. 42.3%; P<.01), and toxicity-related discontinuations of therapy (12.9% and 12.3% vs. 32.1%; P=.004). After day 1, infusional reactions were less frequent with ABLC, but chills/rigors were still higher (21.0% and 24.3% vs. 50.7%; P<.001). Therapeutic success was similar in all 3 groups.
authors.affiliation: Division of Hematology, University of Florida College of Medicine, Gainesville, FL 32610-0277, USA. wingajr@medicine.ufl.edu
authors.forename: J R
authors.initials: JR
authors.lastname: Wingard
authors.forename: M H
authors.initials: MH
authors.lastname: White
authors.forename: E
authors.initials: E
authors.lastname: Anaissie
authors.forename: J
authors.initials: J
authors.lastname: Raffalli
authors.forename: J
authors.initials: J
authors.lastname: Goodman
authors.forename: A
authors.initials: A
authors.lastname: Arrieta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D023341:Chills / Q000139:chemically induced; D004311:Double-Blind Method; D004337:Drug Carriers; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B